Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial

Abstract

Highlights • SECRAB is the largest chemo-radiotherapy trial to date in early breast cancer.• SECRAB showed a positive therapeutic benefit of using adjuvant synchronous chemo-radiotherapy.• Synchronous chemo-radiotherapy should be used for ≤\u202f3 week radiotherapy schedules.• SECRAB results are applicable to patients having CMF or anthracycline-CMF schedules.• Overall survival outcome may increase for patients receiving synchronous anthracycline-CMF.